{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for l root_names_name in Any Name (approximate match)
Status:
Investigational
Source:
NCT00022373: Phase 3 Interventional Unknown status Head and Neck Cancer
(2000)
Source URL:
Class:
PROTEIN
IB-367, a synthetic analog of porcine protegrin, is an antimicrobial peptide. It reduces the local microflora densities and may improve clinical outcomes in patients at risk for the development of oral mucositis.
Status:
Investigational
Source:
NCT03427151: Phase 3 Interventional Completed Lupus Erythematosus, Systemic
(2018)
Source URL:
Class:
PROTEIN
Forigerimod (also known as IPP-201101) a phosphopeptide is being investigated for the treatment of Lupus Erythematosus, Systemic. This drug is completed phase III clinical trials and is ready for licensing.
Status:
Investigational
Source:
NCT00022373: Phase 3 Interventional Unknown status Head and Neck Cancer
(2000)
Source URL:
Class:
PROTEIN
IB-367, a synthetic analog of porcine protegrin, is an antimicrobial peptide. It reduces the local microflora densities and may improve clinical outcomes in patients at risk for the development of oral mucositis.
